---
title: The Future of Pet Oncology: How AI-Driven Targeted Therapies are Revolutionizing Cancer Treatment for Dogs
description: Discover how AI-driven targeted therapies are transforming cancer treatment for dogs. Learn about FidoCure's innovative approach to pet oncology, offering personalized treatments and new hope for canine cancer patients.
image: https://blog.fidocure.com/hubfs/petonc.png
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# The Future of Pet Oncology: How AI-Driven Targeted Therapies are Revolutionizing Cancer Treatment for Dogs
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/the-future-of-pet-oncology-how-ai-driven-targeted-therapies-are-revolutionizing-cancer-treatment-for-dogs) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/the-future-of-pet-oncology-how-ai-driven-targeted-therapies-are-revolutionizing-cancer-treatment-for-dogs) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/the-future-of-pet-oncology-how-ai-driven-targeted-therapies-are-revolutionizing-cancer-treatment-for-dogs)
The global veterinary oncology market has been experiencing remarkable growth, reaching a valuation of [$259.4B](https://www.skyquestt.com/report/veterinary-oncology-market) in 2023. This surge reflects a significant shift in how pet parents approach cancer treatment for their beloved companions. Several factors are driving this expansion: increasing pet ownership rates (accelerated by the [COVID-19 pandemic](https://www.usatoday.com/story/money/2020/09/02/dog-adoption-covid-19-creates-a-thriving-business-for-dogs/5680569002/)), a cultural shift in viewing pets as family members, and advancements in veterinary medicine. As households increasingly view their [pets as family members](https://www.economist.com/business/2024/09/12/people-are-splurging-like-never-before-on-their-pets), they're more willing to invest in sophisticated health treatments, including cancer care. This growing market presents both challenges and opportunities for innovative approaches to pet cancer treatment.
Traditionally, chemotherapy has dominated the veterinary oncology therapy landscape, accounting for approximately [25 percent](https://www.skyquestt.com/report/veterinary-oncology-market) of the market share in 2022. However, this approach comes with considerable drawbacks. Chemotherapy's non-specific targeting affects both cancerous and healthy cells, often leading to severe side effects. Its efficacy can be unpredictable, with some dogs showing little to no improvement, and the treatment's impact on quality of life is a significant concern for many pet parents.
In response to these challenges, FidoCure is revolutionizing veterinary oncology with its innovative approach to precision medicine. By offering personalized, targeted therapies based on each dog's unique cancer profile, FidoCure contrasts sharply with traditional treatments. FidoCure identifies specific mutations driving cancer growth through detailed AI analysis of tumor genetics and reveals which cancer drugs or therapies may be most effective based on a dog's specific mutations.
Furthermore, the beauty of targeted therapies is that many are oral medications, making them far easier to administer than traditional chemotherapy. This simplicity democratizes cancer care, shifting that care from only oncology specialists to general practitioners. With FidoCure, local veterinarians have a new, powerful toolbox to treat cancer. This opens up the possibility for more veterinarians to help more dogs without specialized oncology training or expensive equipment.
As FidoCure continues to use AI-driven targeted therapies to treat dogs with cancer, each dog enrolled in the platform adds invaluable intelligence to FidoCure's genetic database. As this real-world canine clinical cancer database grows, it also improves treatment efficacy and accelerates the development of new precision cancer drugs for both veterinary and human applications.
The future of pet oncology is bright, driven by innovative approaches like FidoCure's AI-driven targeted therapies. As the veterinary oncology market continues its robust growth, precision medicine is reshaping how we approach cancer care for our canine companions. By leveraging cutting-edge technology to analyze each dog's unique cancer profile, FidoCure is not only improving treatment outcomes but giving countless dogs a new leash on life.
## Related Articles
[](https://blog.fidocure.com/fidocure-blog/introducing-fetch-our-ai-engine-that-optimizes-cancer-therapies-for-dogs)
### [Introducing Fetch™: Our AI Engine That Optimizes Cancer Therapies for Dogs](https://blog.fidocure.com/fidocure-blog/introducing-fetch-our-ai-engine-that-optimizes-cancer-therapies-for-dogs)
We’ve always believed that dogs deserve the most advanced medical care possible. Today, we're excited to introduce Fetch™, our proprietary AI engine that is already...
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/introducing-fetch-our-ai-engine-that-optimizes-cancer-therapies-for-dogs)
[](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer)
[Vet](https://blog.fidocure.com/fidocure-blog/tag/vet)
### [Ardent and FidoCure Announce Groundbreaking Partnership](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer)
FOR IMMEDIATE RELEASE
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "FidoCure",
"url" : "https://blog.fidocure.com/fidocure-blog/author/fidocure"
},
"dateModified" : "2024-10-29T13:00:04.722Z",
"datePublished" : "2024-10-29T13:00:00.000Z",
"headline" : "The Future of Pet Oncology: How AI-Driven Targeted Therapies are Revolutionizing Cancer Treatment for Dogs",
"image" : [ "https://blog.fidocure.com/hubfs/petonc.png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/the-future-of-pet-oncology-how-ai-driven-targeted-therapies-are-revolutionizing-cancer-treatment-for-dogs",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```